|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date27 Nov 1974 |
Target- |
Mechanism- |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
仙苓草颗粒对非小细胞肺癌化疗增效减毒的随机双盲、安慰剂、平行对照多中心临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical trial of Xianlingcao granules for enhancing the efficacy and reducing the toxicity of chemotherapy for non-small cell lung cancer
(1)探讨仙苓草颗粒对原发性非小细胞肺癌气滞血瘀证患者合并化疗的有效适应症 (2)观察仙苓草颗粒的安全性
[Translation] (1) To explore the effective indications of Xianlingcao Granules for patients with primary non-small cell lung cancer with Qi stagnation and blood stasis combined with chemotherapy (2) To observe the safety of Xianlingcao Granules
100 Clinical Results associated with Tianjin Tianjiao Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Tianjin Tianjiao Pharmaceutical Co., Ltd.
Zhonghua Xiandai Linchuang Yixue Zazhi
Study on quality standard of rhodiola extract
Author: Ling, Jing-hua ; Yu, Sheng-li ; Shang, Hong
The objective of this paper is to establish the quality standard of rhodiola extractSalidroside and p-tyrosol were qual. analyzed by TLC.Salidroside was quant. measured by HPLC.The results showed that salidroside and p-tyrosol could be identified by TLC.The linear relationship was at the range of 9.16-91.6 μg/mL for salidroside and the average recovery was 100.02%.It was concluded that this method is accurate and highly reproducible.It can be used for the quality control of rhodiola extract
100 Deals associated with Tianjin Tianjiao Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Tianjin Tianjiao Pharmaceutical Co., Ltd.